Kolexia
Edeline Julien Oncologie médicale
Edeline Julien
Oncologie médicale
Centre Eugène Marquis
Rennes, France
335 Activités
349 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Carcinome hépatocellulaire Tumeurs du foie Cholangiocarcinome Tumeurs des voies biliaires Tumeurs des canaux biliaires Métastase tumorale Néphrocarcinome Tumeurs du pancréas

Collaborateurs

Voir plus
Garin Etienne
Garin Etienne
Centre Eugène Marquis, Rennes, France
Blanc Jean-Frederic
Blanc Jean-Frederic
Hôpital Saint-André, Bordeaux, France
Merle Philippe
Merle Philippe
Hôpital La Croix-Rousse, Lyon, France
Rolland Yan
Rolland Yan
Centre Eugène Marquis, Rennes, France

Industries

Voir plus
Servier
20 collaboration(s)
Dernière en 2023
Roche
19 collaboration(s)
Dernière en 2023
MSD
18 collaboration(s)
Dernière en 2023
Ipsen
14 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma: A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (CheckMate 459: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459)
Essai Clinique (BMS)   15 mars 2024
RELATIVITY-106: A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination With Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma
Essai Clinique (BMS)   07 mars 2024
KEYNOTE-966: A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants With Advanced and/or Unresectable Biliary Tract Carcinoma
Essai Clinique (Merck & Co.)   04 mars 2024
ROWAN: An Open-Label, Prospective, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of TheraSphere™ Followed by Durvalumab (Imfinzi®) With Tremelimumab (Imjudo®) for Hepatocellular Carcinoma (HCC)
Essai Clinique (Boston Scientific)   28 février 2024
PROACTIF: A Prospective, Post Approval, Multiple Centre, Open-Label, Non-Interventional, Registry Study to Evaluate Effectiveness of TheraSphere® in Clinical Practice in France
Essai Clinique (Boston Scientific)   21 février 2024
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.
European journal of cancer (Oxford, England : 1990)   06 février 2024
ProActIF-01 Trial: Randomized Study of Evaluation of an Individualized Program of Nutrition and Adapted Physical Activity in Frail Patients With Advanced Lung or Digestive Cancers
Essai Clinique (Institut Curie)   26 janvier 2024
Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trial.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine   11 janvier 2024
Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002): A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants With Advanced Hepatocellular Carcinoma (LEAP-002)
Essai Clinique (Merck & Co.)   05 janvier 2024
Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study: Marqueurs Pronostiques et prédictifs de réponse Aux Traitements Chez Les Patients Atteints de Cancer Des Voies Biliaires : Cohorte Multicentrique ACABi PRONOBIL
Essai Clinique (GERCOR (Multidisciplinary Group in Oncology))   03 janvier 2024